Lung cancer combo trial halted early – only 5 patients enrolled
NCT ID NCT05141357
First seen Jan 04, 2026 · Last updated Jun 24, 2026 · Updated 24 times
Summary
This phase 2 study tested a combination of two drugs—HBI-8000 (tucidinostat) and pembrolizumab (Keytruda)—in people with advanced or metastatic non-small cell lung cancer whose tumors have a specific protein marker (PD-L1). The goal was to see if the combination was safe and effective. However, the trial was terminated early and only enrolled 5 participants, so we have very limited information about how well it works or what side effects may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309, United States
-
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606, United States
-
Frederick Health-JMSCI
Frederick, Maryland, 21702, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Midewestern Regional Medical Center, LLC
Zion, Illinois, 60099, United States
-
Southeastern Regional Medical Center
Newnan, Georgia, 30265, United States
-
Western Regional Medical Center
Goodyear, Arizona, 85338, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI-8000 (tucidinostat) combined with pembrolizumab (Keytruda)
What this could lead to
If it worked, this combination might offer a new treatment option for people with advanced lung cancer whose tumors have a certain protein marker.
What could go wrong
The trial was terminated early with only 5 participants, so there is very little data. It is unclear if the combination is safe or effective, and it may not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.